EC

EcoR1 Capital Portfolio holdings

AUM $2.06B Turnover 46.34%
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
-12.44%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$3.27B
AUM Growth
-$685M
Cap. Flow
+$21.7M
Cap. Flow %
0.66%
Top 10 Hldgs %
61.39%
Holding
65
New
6
Increased
5
Reduced
5
Closed
10
Avg Time Held Equity + Options
1.8 years
Top 10 Avg Time Held Equity + Options
1.6 years
Top 20 Avg Time Held Equity + Options
1.9 years
Avg Time Held Equity only
1.8 years
Top 10 Avg Time Held Equity only
1.6 years
Top 20 Avg Time Held Equity only
1.9 years

Top Buys

Rank Stock Value
1
MORF icon
Morphic Holding, Inc. Common Stock
MORF
+$77M
2
JANX icon
Janux Therapeutics
JANX
+$69M
3
CRGX icon
CARGO Therapeutics
CRGX
+$27.9M
4
BCYC icon
Bicycle Therapeutics
BCYC
+$20.6M
5
ITOS icon
iTeos Therapeutics
ITOS
+$17.9M

Top Sells

Rank Stock Value
1
ACAD icon
Acadia Pharmaceuticals
ACAD
+$75M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$65.8M
3
ALEC icon
Alector
ALEC
+$24.4M
4
NKTX icon
Nkarta
NKTX
+$21.6M
5
OVID icon
Ovid Therapeutics
OVID
+$18.7M

Sector Composition

Rank Sector Weight
1 Healthcare 99.88%
2 Miscellaneous 0.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
APLS icon
1
DELISTED
Apellis Pharmaceuticals
APLS
$445M 13.62%
11,607,425
+250,000
+2% +$11.3M
2021 Q4
10 quarters
PRTA icon
2
Prothena Corp
PRTA
$430M
$239M 7.31%
11,584,280
– –
2018 Q4
22 quarters
SRPT icon
3
Sarepta Therapeutics
SRPT
$1.78B
$222M 6.8%
1,407,322
-512,513
-27% -$65.8M
2023 Q4
2 quarters
ANAB icon
4
AnaptysBio
ANAB
$1.39B
$188M 5.77%
7,521,024
– –
2019 Q4
18 quarters
CRNX icon
5
DELISTED
Crinetics Pharmaceuticals
CRNX
$186M 5.69%
4,155,375
– –
2021 Q4
10 quarters
ARVN icon
6
Arvinas
ARVN
$445M
$179M 5.48%
6,726,491
– –
2021 Q4
10 quarters
MORF icon
7
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$170M 5.19%
4,982,945
+2,598,561
+109% +$77M
2019 Q2
20 quarters
LKFT icon
8
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.93B
$143M 4.36%
5,756,268
– –
2021 Q3
11 quarters
KURA icon
9
Kura Oncology
KURA
$857M
$120M 3.66%
5,806,871
– –
2015 Q4
34 quarters
TNGX icon
10
Tango Therapeutics
TNGX
$3.74B
$114M 3.5%
13,330,736
– –
2020 Q3
15 quarters
ZYME icon
11
Zymeworks
ZYME
$1.78B
$114M 3.5%
13,437,473
– –
2022 Q4
6 quarters
JAZZ icon
12
Jazz Pharmaceuticals
JAZZ
$13.6B
$108M 3.31%
1,013,952
– –
2023 Q2
4 quarters
XNCR icon
13
Xencor
XNCR
$1.74B
$101M 3.09%
5,330,416
– –
2018 Q4
22 quarters
CRSP icon
14
CRISPR Therapeutics
CRSP
$4.86B
$75M 2.3%
1,389,276
– –
2024 Q1
1 quarter
JANX icon
15
Janux Therapeutics
JANX
$1.05B
$61.6M 1.88%
+1,469,818
New +$69M
2024 Q2
0 quarters
NUVB icon
16
Nuvation Bio
NUVB
$1.64B
$56.1M 1.72%
19,209,643
– –
2021 Q1
13 quarters
CNTA
17
DELISTED
Centessa Pharmaceuticals
CNTA
$51.6M 1.58%
5,714,404
+95,625
+2% +$907K
2021 Q2
12 quarters
ITOS icon
18
DELISTED
iTeos Therapeutics
ITOS
$48.2M 1.48%
3,249,835
+1,250,586
+63% +$17.9M
2023 Q4
2 quarters
IMNM icon
19
Immunome
IMNM
$2.03B
$46.9M 1.44%
3,879,415
– –
2023 Q4
2 quarters
NGNE icon
20
Neurogene
NGNE
$443M
$46.3M 1.42%
1,271,342
– –
2023 Q4
2 quarters
THRD icon
21
DELISTED
Third Harmonic Bio
THRD
$41.4M 1.27%
3,182,444
– –
2023 Q1
5 quarters
MRSN icon
22
DELISTED
Mersana Therapeutics
MRSN
$38.9M 1.19%
774,588
– –
2023 Q3
3 quarters
VYGR icon
23
Voyager Therapeutics
VYGR
$123M
$31M 0.95%
3,917,546
– –
2021 Q3
11 quarters
RNAM
24
DELISTED
Avidity Biosciences
RNAM
$30.9M 0.95%
757,576
– –
2024 Q1
1 quarter
TCRX icon
25
TScan Therapeutics
TCRX
$14.6M
$29.3M 0.89%
5,000,000
– –
2023 Q2
4 quarters
1
2 3

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q2 2024 Portfolio in Review

As of Q2 2024, EcoR1 Capital held 65 positions worth $3.27B, down 17% from $3.95B the previous quarter. Its ten largest holdings account for 61% of the portfolio.

EcoR1 Capital's Q2 2024 filing shows 6 new, 5 increased, 5 reduced and 10 closed positions. Its largest new stake was Janux Therapeutics: 1,469,818 shares worth $61.6M. The largest sale was Acadia Pharmaceuticals, an estimated $75M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Miscellaneous.

  • EcoR1 Capital's largest Q2 2024 buy was Janux Therapeutics: 1,469,818 shares worth $61.6M.
  • EcoR1 Capital added most to Morphic Holding, Inc. Common Stock in Q2 2024, an estimated $77M increase.
  • EcoR1 Capital's biggest Q2 2024 reduction was Acadia Pharmaceuticals, cutting an estimated $75M.
  • EcoR1 Capital fully exited Alector in Q2 2024, selling an estimated $24.4M.
  • EcoR1 Capital's ten largest holdings make up 61% of its $3.27B portfolio in Q2 2024.
  • EcoR1 Capital opened 6 new positions and closed 10 in Q2 2024.
  • EcoR1 Capital's portfolio value fell 17% quarter-over-quarter to $3.27B.

Based on EcoR1 Capital's 13F filing for Q2 2024, filed 14 Aug 2024.